v3.26.3
XOMA Acquisition - Intangible Assets Acquired (Details) - XOMA Acquisition
$ in Thousands
Jul. 14, 2026
USD ($)
Business Combination  
Fair value $ 103,000
Mezagitamab  
Business Combination  
Fair value $ 41,500
Useful Life (years) 14 years
Ersodetug  
Business Combination  
Fair value $ 24,600
Useful Life (years) 13 years
Anti-TL1A  
Business Combination  
Fair value $ 16,400
Useful Life (years) 8 years
Kinnate programs  
Business Combination  
Fair value $ 5,500
Useful Life (years) 6 years
Ficlatuzumab  
Business Combination  
Fair value $ 5,100
Useful Life (years) 12 years
Rilvegostomig  
Business Combination  
Fair value $ 3,900
Useful Life (years) 4 years
Cetrelimab  
Business Combination  
Fair value $ 3,700
Useful Life (years) 10 years
Phage display library  
Business Combination  
Fair value $ 2,300
Useful Life (years) 10 years